Interleukin-6 Receptor Blockade can Increase the Risk of Nonalcoholic Fatty Liver Disease: Indications From Mendelian Randomization

Background: Interleukin-6 receptor (IL-6R) blockade has been approved for inflammation-associated diseases and whether it is effective in treating non-alcoholic fatty liver disease (NAFLD) is still unknown. Methods: A target-based Mendelian randomization was performed to appraise whether inhibiting...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shuxuan, Chen, Lanlan, Lv, Guoyue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209733/
https://www.ncbi.nlm.nih.gov/pubmed/35747747
http://dx.doi.org/10.3389/fphar.2022.905936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209733/
https://www.ncbi.nlm.nih.gov/pubmed/35747747
http://dx.doi.org/10.3389/fphar.2022.905936

Ejemplares similares